Novavax Inc (NVAX.OQ)
24 Sep 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2011||Independent Chairman of the Board|
|70||2018||President, Chief Executive Officer, Director|
|58||2018||Senior Vice President, Chief Business Officer, Chief Financial Officer and Treasurer|
|64||2016||President, Research and Development|
|53||2014||Senior Vice President, General Counsel, Corporate Secretary|
- BRIEF-Novavax Q1 Loss Per Share $0.14
- BRIEF-Novavax Reports Q1 Loss Per Share $0.14
- BRIEF-Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019
- BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share
- BRIEF-Novavax Announces Proposed Public Offering Of Common Stock